On July 20, 2020 INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported the closing of its previously announced underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share and the exercise in full of the underwriters’ option to purchase an additional 326,086 shares of common stock (Press release, INmune Bio, JUL 20, 2020, View Source [SID1234562121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A total of 2,500,000 shares of common stock were issued in the offering, including the full exercise of the over-allotment option.

The gross proceeds to INmune from this offering are approximately $23.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by INmune. INmune intends to use the net proceeds from the offering for general corporate purposes, including to support research and development, including clinical trials.

BTIG, LLC acted as sole book-running manager of the offering, and National Securities Corporation acted as a co-manager.

The offering was made pursuant to the shelf registration statement on Form S-3 (File No. 333-237368) that was filed with the Securities and Exchange Commission (the "SEC") on March 24, 2020 and became effective on April 2, 2020, including the related base shelf prospectus, as supplemented by the prospectus supplement dated July 16, 2020. The final prospectus supplement and accompanying base shelf prospectus are available on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On July 20, 2020 Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence ("A.I."), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, reported that entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lantern’s oncology drug candidates, LP-300 and LP184 (Press release, Lantern Pharma, JUL 20, 2020, View Source [SID1234562120]). Lantern Pharma filed an 8-K on Thursday, July 16 describing a recent agreement for GMP manufacturing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lantern’s LP-300 is a small molecule drug candidate currently in preparation to enter phase 2 clinical trials in a growing, but unaddressed, type of non-small cell lung cancer (NSCLC) among never-smokers. Lantern is focused on developing LP-300 as a potential first-in-class combination therapy for never smoking (or non-smoking) NSCLC patients with histologically defined adenocarcinoma. NSCLC among never and non-smokers has a distinct molecular profile and according to the American Cancer Society, as many as 20% of people who die from lung cancer in the United States every year have never smoked or used any other form of tobacco. Leading researchers have started to classify lung cancer in never and non-smokers as having unique and distinct clinical, biological and pathological characteristics that have the potential to be impacted by new therapeutic options. According to market research, and data analytics firm, GlobalData, approximately $10 billion USD will be spent annually on NSCLC therapies in 2020 in the leading eight markets (by annual drug sales), with approximately $4 billion in the US.

Lantern’s LP-184 is a small molecule drug candidate currently in preclinical development for certain genomically defined solid tumors that overexpress certain RNA, as well as for glioblastoma multiforme (GBM). Lantern is currently planning to enter a Phase 1 clinical trial with this drug candidate in late 2021 or early 2022, after finalizing further biomarker studies with leading researchers, and after completing IND-enabling studies. Lantern estimates that, by 2025, potential annual sales for therapies in the genomically defined solid tumors targeted by LP-184 will be over $2.5 billion USD globally, and that potential annual sales for therapies to treat GBM will be nearly $1 billion globally. Both molecules have been advanced using Lantern’s proprietary RADR A.I. platform. With nearly 500 million data points, the RADR A.I. platform uses machine learning techniques, genomics, and computational biology methods to accelerate drug development by accelerating the discovery of potential mechanisms of action and developing genomic and biomarker signatures that correlate to drug UNDER EMBARGO UNTIL 8:00 AM EASTERN MONDAY, 07/20/20 response in cancer patients.

Both molecules, LP-300 and LP-184, are being developed with the vision of pairing them with companion diagnostics generated, in-part by RADR, to enable precision medicine trials and selection of patients with the highest probability of benefiting from the drug and offering the potential for best-in-class outcomes.

Panna Sharma, CEO and President of Lantern Pharma, stated, "the launch of manufacturing activities with our partners represents key steps in establishing a specialized global manufacturing network that can provide Lantern with critical scalability, flexibility and innovation to help maximize the impact of our capital resources and efficiently prepare our drug supply for our clinical trials and studies." Sharma continued, "These key capabilities are especially important now as we advance LP-300 and LP-184 towards commencement of clinical trials that can likely shape the timing and terms of potential future partnering discussions."

On July 20, 2020 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) reported that it will announce results for the first quarter ended June 30, 2020 on Wednesday, July 29th, 2020 after the Board Meeting (Press release, Dr Reddy’s, JUL 20, 2020, View Source [SID1234562117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Summary of Events

Event Date and Time Medium
Release of financial results July 29th, after the Board Meeting Stock Exchange, Media, Company website, Business wire, Email

Press meet presentation Will be available on the Company’s website Company’s website www.drreddys.com

Earnings Call July 29th, 5:30 PM IST / 8:00 AM EDT
Hosted by the Company

(Details below)

Playback of Earnings Call After the earnings call till August 6th, 2020 Details below

Transcript of the Earnings call Will be available on the Company’s website URL available on Company’s website, www.drreddys.com

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Play Back

The play back will be available after the earnings call, till August 6th, 2020. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 58336.

On July 20, 2020 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, reported that it has repaid the remaining 12.5% debentures issued in April 2018 (Press release, ImmunoPrecise Antibodies, JUL 20, 2020, View Source [SID1234562116]). In addition, IPA has received CAD$3,811,205 in connection with the exercise of previously issued warrants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Over the last two months we have strengthened our balance sheet with the oversubscribed convertible debenture financing and the receipt of approximately $3.8 million from warrant exercises," states Jennifer Bath, Chief Executive Officer of ImmunoPrecise. "The early repayment of the 2018 debentures removed a significant short-term debt obligation."

Of the CAD$3.8 million in warrants exercised, warrant holders exercised 875,000 warrants at CAD$1.00; 1,357,971 warrants at CAD$0.70 per share and 1,588,500 warrants were exercised at CAD$1.25 per share.

On July 20, 2020 Pfenex Inc. (NYSE American: PFNX) reported that it will report its financial results for the first quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020 (Press release, Pfenex, JUL 20, 2020, View Source [SID1234562115]). Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast
Thursday, August 6th @ 1:30 PM Pacific Time (4:30 PM Eastern Time)
Domestic: 877-705-6003 (Domestic)
International: 201-493-6725
Conference ID: 13705182

The call will also be webcast and can be accessed from the Investors section of the Company’s website at www.pfenex.com or View Source

A replay of the call will also be available through August 13th. Participants may access the replay from the Investors section of the Company’s website at www.pfenex.com or View Source